BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24604524)

  • 1. Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Golüke H; von Scheidt W; Kuch B; Peters A; Meisinger C
    Clin Res Cardiol; 2014 Aug; 103(8):655-64. PubMed ID: 24604524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
    Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value.
    Lee JH; Yang DH; Park HS; Cho Y; Jeong MH; Kim YJ; Kim KS; Hur SH; Seong IW; Hong TJ; Cho MC; Kim CJ; Jun JE; Park WH; Chae SC;
    Am Heart J; 2010 Jun; 159(6):1012-9. PubMed ID: 20569714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
    Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Barron HV; Michaels AD; Maynard C; Every NR
    J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of early follow-up after acute myocardial infarction with higher rates of medication use.
    Daugherty SL; Ho PM; Spertus JA; Jones PG; Bach RG; Krumholz HM; Peterson ED; Rumsfeld JS; Masoudi FA
    Arch Intern Med; 2008 Mar; 168(5):485-91; discussion 492. PubMed ID: 18332293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study.
    Gunnell AS; Einarsdóttir K; Sanfilippo F; Liew D; Holman CD; Briffa T
    Heart; 2013 Sep; 99(18):1353-8. PubMed ID: 23886604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993.
    Koenig W; Löwel H; Lewis M; Hörmann A
    Eur Heart J; 1996 Aug; 17(8):1199-206. PubMed ID: 8869861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
    Zeymer U; Jünger C; Zahn R; Bauer T; Bestehorn K; Senges J; Gitt A
    Curr Med Res Opin; 2011 Aug; 27(8):1563-70. PubMed ID: 21682553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
    Hara M; Sakata Y; Nakatani D; Suna S; Usami M; Matsumoto S; Sugitani T; Nishino M; Sato H; Kitamura T; Nanto S; Hamasaki T; Hori M; Komuro I;
    Am J Cardiol; 2014 Jul; 114(1):1-8. PubMed ID: 24819900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.